Point-of-care glucose and lipid profile measures using a human point-of-care device in mouse models of type 2 diabetes mellitus, aging, and Alzheimer disease

• Verfasst von: Smyth, Brendan J. [VerfasserIn]
• Verfasst von: Polaski, Rachel S [VerfasserIn]
• Verfasst von: Safer, Anton [VerfasserIn]
• Verfasst von: Boettcher, Flint A. [VerfasserIn]
• Verfasst von: Konrad-Martin, Dawn [VerfasserIn]
• Verfasst von: Gratton, Michael Anne [VerfasserIn]
• Titel: Point-of-care glucose and lipid profile measures using a human point-of-care device in mouse models of type 2 diabetes mellitus, aging, and Alzheimer disease
• Verf.angabe: Brendan J Smyth, Rachel S Polaski, Anton Safer, Flint A Boettcher, Dawn Konrad-Martin, Michael Anne Gratton
• E-Jahr: 2021
• Jahr: 1. November 2021
• Umfang: 7 S.
• Fussnoten: Gesehen am 20.01.2022
• Titel Quelle: Enthalten in: American Association for Laboratory Animal ScienceJournal of the American Association for Laboratory Animal Science
• Ort Quelle: Memphis, Tenn. : AALAS, 1993
• Jahr Quelle: 2021
• Band/Heft Quelle: 60(2021), 6 vom: Nov., Seite 609-615
• DOI: doi:10.30802/AALAS-JAALAS-21-000011
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1786561859

Abstract

A point-of-care (POC) device to measure mouse glucose and lipid profiles is an important unmet need for cost-effective, immediate decision making in research. We compared metabolic analyte profiles obtained using a human clinical POC device with those from a veterinary laboratory chemical - analyzer (LCA). Unfasted terminal blood samples were obtained by cardiac puncture from C57Bl/6J mice used in a diet-induced obesity model of type 2 diabetes mellitus; age-matched C57Bl/6J controls; a transgenic mouse model of Alzheimer's disease on a C57BL/6J background (16 wk old); and aged - C57BL/6J mice (24 to 60 wk old). Aliquots of the blood were immediately assayed onsite using the POC device. Corresponding serum aliquots were sent analyzed by LCA. Measures from the POC and LCA devices were compared by using the Bland-Altman and Passing-Bablok methods. Of a total - of 40 aliquots, LCA results were within reported reference ranges for each model. POC results that fell beyond the device range were excluded from the analyses. The coefficient of determination and Passing-Bablok analysis demonstrated that POC glucose and HDL had the best agreement with - LCA. The Bland-Altman analysis found no value-dependent bias in glucose and no significant bias in HDL. The remaining lipid analytes (cholesterol and triglyceride) showed significant bias. Until an improved, validated mouse POC device with lipid profile capability is available, the POC - device that we tested appears adequate for screening glucose and HDL in mouse blood. Disadvantages of this clinical POC device are the narrow human ranges relative to ranges found in mice and its limited precision as compared with the LCA. This study demonstrates that when the samples are - within the device range limits, this human POC device can accurately track metabolic syndrome and be used to compare patterns in glucose and HDL.